(155 days)
Not Found
No
The device description details a standard clinical chemistry assay based on a chemical reaction and spectrophotometric measurement, with no mention of AI/ML components or data processing methods indicative of AI/ML.
No
This device is an in vitro diagnostic assay used for the quantitative determination of magnesium levels in bodily fluids, which aids in diagnosis. It does not provide any treatment or therapeutic function.
Yes
The "Intended Use / Indications for Use" section explicitly states that "Magnesium measurements are used in the diagnosis and treatment of hypomagnesemia ... and hypermagnesemia." This indicates the device aids in the diagnosis of medical conditions.
No
The device description clearly states it is an "in vitro diagnostic assay" that utilizes a chemical reaction with an arsenazo dye and measures absorbance at 550 nm. This indicates a physical reagent and measurement system, not a software-only device.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states it is "used for the quantitation of magnesium in human serum, plasma, or urine." This involves testing samples taken from the human body.
- Device Description: The description clearly states "Magnesium is an in vitro diagnostic assay". It also describes the process of analyzing a sample (serum, plasma, or urine) using a chemical reaction and measuring absorbance, which is a typical method for in vitro diagnostics.
- Performance Studies: The performance studies describe testing the assay's performance using human samples (serum and urine) and comparing it to another assay.
- Predicate Device: The mention of a "Predicate Device" with a K number (K811194) is a strong indicator that this device is being submitted for regulatory review as an IVD, as predicate devices are used for comparison in the IVD regulatory process.
All of these points align with the definition and characteristics of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The Magnesium assay is used for the quantitation of magnesium in human serum, plasma, or urine. Magnesium measurements are used in the diagnosis and treatment of hypomagnesemia (abnormally low serum levels of magnesium) and hypermagnesemia (abnormally high serum levels of magnesium).
Product codes
JGJ
Device Description
Magnesium is an in vitro diagnostic assay for the quantitative determination of magnesium in human serum, plasma, or urine. The Magnesium assay is a clinical chemistry assay which utilizes an arsenazo dye which binds preferentially with magnesium. The absorbance of the arsenazo magnesium complex is measured at 550 nm and is proportional to the concentration of magnesium present in the sample. Calcium interference is prevented by incorporation of a calcium chelating agent.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Comparative performance studies were conducted using the AEROSET™ System. The Magnesium assay method comparison yielded acceptable correlation with the Boehringer Mannheim Magnesium assay on the Hitachi 717 Analyzer for both the serum and the urine applications. For the serum application, the correlation coefficient = 0.9884, slope = 0.961 and the Y-intercept = 0.134 mEq/L. For the urine application, the correlation coefficient = 0.9866, slope = 1.068 and the Y-intercept = -0.222 mEq/L. Precision studies were conducted using the Magnesium assay. Within-run. between-run, and between-day studies were performed using two levels of control material. For the serum application, the total %CV for Level 1/Panel 101 is 4.4% and Level 2/Panel 102 is 3.4%. For the urine application, the total %CV for Level 1/Panel 201 is 4.5% and Level 2/Panel 202 is 2.9%. The Magnesium assay is linear up to 7.79 mEq/L for the serum application, and 21.7 mEq/L for the urine application. The limit of quantitation (sensitivity) of the Magnesium assay is 0.38 mEq/L. These data demonstrate that the performance of the Magnesium assay is substantially equivalent to the performance of the Boehringer Mannheim Magnesium assay on the Hitachi 717 Analyzer for both serum and urine applications.
Key Metrics
Correlation coefficient (serum) = 0.9884, slope (serum) = 0.961, Y-intercept (serum) = 0.134 mEq/L.
Correlation coefficient (urine) = 0.9866, slope (urine) = 1.068, Y-intercept (urine) = -0.222 mEq/L.
Total %CV (serum, Level 1) = 4.4%, Total %CV (serum, Level 2) = 3.4%.
Total %CV (urine, Level 1) = 4.5%, Total %CV (urine, Level 2) = 2.9%.
Linearity (serum) up to 7.79 mEq/L.
Linearity (urine) up to 21.7 mEq/L.
Limit of quantitation (sensitivity) = 0.38 mEq/L.
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 862.1495 Magnesium test system.
(a)
Identification. A magnesium test system is a device intended to measure magnesium levels in serum and plasma. Magnesium measurements are used in the diagnosis and treatment of hypomagnesemia (abnormally low plasma levels of magnesium) and hypermagnesemia (abnormally high plasma levels of magnesium).(b)
Classification. Class I.
0
510(k) Summary
OCT 2 3 1998
Submitter's Name/Address Abbott Laboratories 1920 Hurd Drive Irving, Texas 75038
Contact Person Mark Littlefield Section Manager MS 1-8 Regulatory Affairs (972) 518-6062 Fax (972) 753-3367
| Date of Preparation of this Summary: | May 20, 1998 |
|---|---|
| Device Trade or Proprietary Name: | Mg |
| Device Common/Usual Name or Classification Name: | Magnesium |
| Classification Number/Class: | 75JGJ/Class I |
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
The assigned 510(k) number is:
Test Description:
Magnesium is an in vitro diagnostic assay for the quantitative determination of magnesium in human serum, plasma, or urine. The Magnesium assay is a clinical chemistry assay which utilizes an arsenazo dye which binds preferentially with magnesium. The absorbance of the arsenazo magnesium complex is measured at 550 nm and is proportional to the concentration of magnesium present in the sample. Calcium interference is prevented by incorporation of a calcium chelating agent.
Substantial Equivalence:
The Magnesium assay is substantially equivalent to the Boehringer Mannheim® Magnesium assay (K811194) on the Hitachi® 717 Analyzer for both the serum and the urine applications.
Magnesium 510(k) May 20, 1998 Magf.lwp
Section II Page 1
000011
1
These assays yield similar Performance Characteristics.
Similarities:
- . Both assavs are in vitro clinical chemistry methods.
- . Both assays can be used for the quantitative determination of magnesium.
- Both assays yield similar clinical results. o
Differences:
- There is a minor difference between the serum assay ranges. .
Intended Use:
The Magnesium assay is used for the quantitation of magnesium in human serum, plasma, or urine.
Performance Characteristics:
Comparative performance studies were conducted using the AEROSET™ System. The Magnesium assay method comparison yielded acceptable correlation with the Boehringer Mannheim Magnesium assay on the Hitachi 717 Analyzer for both the serum and the urine applications. For the serum application, the correlation coefficient = 0.9884, slope = 0.961 and the Y-intercept = 0.134 mEq/L. For the urine application, the correlation coefficient = 0.9866, slope = 1.068 and the Y-intercept = -0.222 mEq/L. Precision studies were conducted using the Magnesium assay. Within-run. between-run, and between-day studies were performed using two levels of control material. For the serum application, the total %CV for Level 1/Panel 101 is 4.4% and Level 2/Panel 102 is 3.4%. For the urine application, the total %CV for Level 1/Panel 201 is 4.5% and Level 2/Panel 202 is 2.9%. The Magnesium assay is linear up to 7.79 mEq/L for the serum application, and 21.7 mEq/L for the urine application. The limit of quantitation (sensitivity) of the Magnesium assay is 0.38 mEq/L. These data demonstrate that the performance of the Magnesium assay is substantially equivalent to the performance of the Boehringer Mannheim Magnesium assay on the Hitachi 717 Analyzer for both serum and urine applications.
4
2
Conclusion:
The Magnesium assay is substantially equivalent to the Boehringer Mannheim Magnesium assay on the Hitatchi 717 Analyzer for the serum and urine applications as demonstrated by results obtained in the studies.
Magnesium 510(k) May 20, 1998
Magf.lwp
Section II Page 3
Image /page/2/Picture/4 description: The image shows a sequence of numbers, specifically "0000013". The numbers are printed in a somewhat distressed or worn font, giving them a slightly aged appearance. The digits are clearly visible against the background.
3
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" arranged around the perimeter. Inside the circle is a stylized symbol featuring three abstract human profiles facing to the right, connected by flowing lines that resemble a ribbon or banner.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
OCT 2 3 1998
Mark Littlefield Section Manager, Regulatory Affairs Abbott Laboratories 1920 Hurd Drive Irving, Texas 75038
K981791 Re : Maqnesium Requlatory Class: I Product Code: JGJ Dated: October 13, 1998 Received: October 13, 1998
Dear Mr. Littlefield:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions The general controls provisions of the Act of the Act. include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major requlations affecting your device can be found in the Code of Federal Requlations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical General regulation (21 CFR Part 820) and that, Devices: through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or requlations.
4
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to
premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".
sincerely yours,
Steven Bitman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
510(k) Number (if known):
Device Name: _________________________________________________________________________________________________________________________________________________________________
Indications For Use:
The Magnesium assay is used for the quantitation of magnesium in human serum, plasma, or urine. Magnesium measurements are used in the diagnosis and treatment of hypomagnesemia (abnormally low serum levels of magnesium) and hypermagnesemia (abnormally high serum levels of magnesium).
| (Division Sign-Off) | |
|---|---|
| Division of Clinical Laboratory Devices | |
| 510(k) Number | KC981791 |
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
| Prescription Use | ✓ |
|---|---|
| (Per 21 CFR 801.109) | OR |
| Over-The-Counter Use ______ |
(Optional Format 1-2-96)
000000000